PACS Group, Inc. (PACS) Spending and interest coverage
- R&D / revenue · 12 months: Value (m); Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value 1.34%; Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | (m) | Research and development expense / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Stock-based compensation / revenue · 12 months | 1.34% | Share-based compensation / revenue. Period ending 2026-06-30. $74.44M ÷ $5.55B × 100 ≈ 1.34% |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | (m) | |
| Revenue | 5.55B USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Stock-based compensation | 74.44M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | 410.32M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $5.55B | $74.44M | $410.32M | (m) | (m) | 1.34% | (m) | (m) |
| 2026-03-31 | (m) | $5.43B | $62.22M | $381.49M | (m) | (m) | 1.15% | (m) | (m) |
| 2025-12-31 | (m) | $5.29B | $54.07M | $309.60M | (m) | (m) | 1.02% | (m) | (m) |
| 2025-09-30 | (m) | $5.14B | $50.63M | $286.89M | (m) | (m) | 0.99% | (m) | (m) |
| 2025-06-30 | (m) | $4.82B | $50.41M | $223.58M | (m) | (m) | 1.05% | (m) | (m) |
| 2025-03-31 | (m) | $4.44B | $127.75M | $105.90M | (m) | (m) | 2.87% | (m) | (m) |
| 2024-12-31 | (m) | $4.09B | $115.54M | $123.07M | (m) | (m) | 2.83% | (m) | (m) |
| 2024-09-30 | (m) | $3.73B | $103.24M | $113.63M | (m) | (m) | 2.77% | (m) | (m) |
| 2024-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-12-31 | (m) | $3.11B | $0.00 | $207.77M | (m) | (m) | 0.00% | (m) | (m) |
| 2023-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-12-31 | (m) | $2.40B | $0.00 | $229.36M | (m) | (m) | 0.00% | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NATIONAL HEALTHCARE CORP (NHC) | United States | $3.473B | 23.65 |
| ENSIGN GROUP, INC (ENSG) | United States | $10.098B | 24.68 |